<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03166618</url>
  </required_header>
  <id_info>
    <org_study_id>VOLUMA-007</org_study_id>
    <nct_id>NCT03166618</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of JUVÉDERM VOLUMA® XC Injectable Gel for Correction of Temple Hollowing</brief_title>
  <official_title>A Multicenter, Single-Blind, Randomized, Parallel-Group, Controlled Study of the Safety and Effectiveness of JUVÉDERM VOLUMA® XC Injectable Gel for Correction of Temple Hollowing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and effectiveness of JUVÉDERM VOLUMA XC injectable gel in
      adult participants seeking correction of temple hollowing.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Business decision to stop the program.
  </why_stopped>
  <start_date type="Actual">April 24, 2017</start_date>
  <completion_date type="Actual">July 21, 2017</completion_date>
  <primary_completion_date type="Actual">July 21, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With at Least a 1-Point Improvement (Decrease) in Both Temples as Assessed by the Evaluating Investigator Using the Allergan Temple Hollowing Scale (ATHS)</measure>
    <time_frame>Change from Baseline to Month 3</time_frame>
    <description>The Evaluating Investigator will assess the participant's temple hollowing using the ATHS 5-point scale where: 0=convex, rounded temple to 4=severe, deeply recessed, sunken appearance. A 1-point decrease from Baseline indicates improvement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants &quot;Improved&quot; or &quot;Much Improved&quot; as Assessed by the Evaluating Investigator Using the Global Aesthetic Improvement Scale (GAIS)</measure>
    <time_frame>Month 3</time_frame>
    <description>The Evaluating Investigator will assess the participant's temple area using the GAIS 5-point scale where: 2=much improved, 1=improved, 0=no change, -1=worse and -2=much worse. The percentage of participants who the Evaluating Investigator assesses as 2=much improved or 1=improved will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants &quot;Improved&quot; or &quot;Much Improved&quot; as Assessed by the Participant Using the GAIS</measure>
    <time_frame>Month 3</time_frame>
    <description>The participant will assess their temple area using the GAIS 5-point scale where: 2=much improved, 1=improved, 0=no change, -1=worse and -2=much worse. The percentage of participants who assess themselves as 2=much improved or 1=improved will be reported.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Temple Hollowing</condition>
  <arm_group>
    <arm_group_label>VOLUMA® XC Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be treated with JUVÉDERM® VOLUMA® XC injectable gel in both temples (area above the eye). Participants are eligible for touch-up treatment 30 days later.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control_No Treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No treatment is administered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Juvéderm® VOLUMA XC</intervention_name>
    <description>Juvéderm® VOLUMA XC hyaluronic acid injectable gel</description>
    <arm_group_label>VOLUMA® XC Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -Has temple hollowing and is seeking restoration in the temple area.

        Exclusion Criteria:

          -  Has temple hollowing due to due to trauma, congenital malformations, or lipodystrophy

          -  Has received permanent facial implants in the face or neck

          -  Has undergone fat injections

          -  Has tattoos, piercings, facial hair or scars that would interfere with visual
             assessment of the temple

          -  Has undergone semipermanent dermal filler treatment in the temple or mid-face within
             the past 36 months

          -  Has undergone dermal filler injections above the subnasale within the past 24 months

          -  Has temporal arteritis or history of temporal arteritis

          -  Has temporomandibular joint dysfunction

          -  Has eye inflammation or infection

          -  Has a history of detached retina, retinal vascular occlusion, narrow angle glaucoma,
             or neovascular eye disease

          -  Has ever received a facelift, browlift, or facial reconstructive surgery

          -  Has undergone mesotherapy or cosmetic treatment (laser, photomodulation, intense
             pulsed light, radio frequency, dermabrasion, moderate or greater depth chemical peel,
             liposuction, lipolysis, or other ablative procedures) anywhere in the face or neck or
             botulinum toxin injections within the past 6 months

          -  Has experienced trauma to the temple within the past 6 months or has residual
             deficiencies, deformities, or scarring

          -  Has a tendency to develop hypertrophic scarring

          -  Has a history of anaphylaxis or allergy to lidocaine (or any amide-based anesthetics),
             hyaluronic acid products, or Streptococcal protein

          -  Has porphyria or untreated epilepsy

          -  Has active autoimmune disease

          -  Has current cutaneous or mucosal inflammatory or infectious processes

          -  Is on a lidocaine, anticoagulation therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nikki Amaratunge</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Skin Care and Laser Physicians of Beverly Hills</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://allerganclinicaltrials.com</url>
    <description>More Information</description>
  </link>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>March 6, 2017</study_first_submitted>
  <study_first_submitted_qc>May 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 25, 2017</study_first_posted>
  <results_first_submitted>July 20, 2018</results_first_submitted>
  <results_first_submitted_qc>October 16, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 18, 2018</results_first_posted>
  <last_update_submitted>October 16, 2018</last_update_submitted>
  <last_update_submitted_qc>October 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 24, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/18/NCT03166618/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Up to 189 subjects were planned; 1 subject was enrolled but did not receive treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>VOLUMA® XC Treatment</title>
          <description>Participants will be treated with JUVÉDERM® VOLUMA® XC injectable gel in both temples (area above the eye). Participants are eligible for touch-up treatment 30 days later.</description>
        </group>
        <group group_id="P2">
          <title>Control_No Treatment</title>
          <description>No treatment is administered.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study was Terminated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Up to 189 subjects were planned; 1 subject was enrolled in the control_No Treatment arm. Due to confidentiality considerations, baseline data is not being provided to protect participant privacy.</population>
      <group_list>
        <group group_id="B1">
          <title>VOLUMA® XC Treatment</title>
          <description>Participants will be treated with JUVÉDERM® VOLUMA® XC injectable gel in both temples (area above the eye). Participants are eligible for touch-up treatment 30 days later.</description>
        </group>
        <group group_id="B2">
          <title>Control_No Treatment</title>
          <description>No treatment is administered.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="0"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>participants</units>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                </category>
                <category>
                  <title>Male</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                </category>
                <category>
                  <title>Asian</title>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                </category>
                <category>
                  <title>Black or African American</title>
                </category>
                <category>
                  <title>White</title>
                </category>
                <category>
                  <title>More than one race</title>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least a 1-Point Improvement (Decrease) in Both Temples as Assessed by the Evaluating Investigator Using the Allergan Temple Hollowing Scale (ATHS)</title>
        <description>The Evaluating Investigator will assess the participant's temple hollowing using the ATHS 5-point scale where: 0=convex, rounded temple to 4=severe, deeply recessed, sunken appearance. A 1-point decrease from Baseline indicates improvement.</description>
        <time_frame>Change from Baseline to Month 3</time_frame>
        <population>Up to 189 subjects were planned; 1 subject was enrolled in the control_No Treatment arm. Terminated study; no treatment was administered and no analyses were conducted.</population>
        <group_list>
          <group group_id="O1">
            <title>VOLUMA® XC Treatment</title>
            <description>Participants will be treated with JUVÉDERM® VOLUMA® XC injectable gel in both temples (area above the eye). Participants are eligible for touch-up treatment 30 days later.</description>
          </group>
          <group group_id="O2">
            <title>Control_No Treatment</title>
            <description>No treatment is administered.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least a 1-Point Improvement (Decrease) in Both Temples as Assessed by the Evaluating Investigator Using the Allergan Temple Hollowing Scale (ATHS)</title>
          <description>The Evaluating Investigator will assess the participant's temple hollowing using the ATHS 5-point scale where: 0=convex, rounded temple to 4=severe, deeply recessed, sunken appearance. A 1-point decrease from Baseline indicates improvement.</description>
          <population>Up to 189 subjects were planned; 1 subject was enrolled in the control_No Treatment arm. Terminated study; no treatment was administered and no analyses were conducted.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants &quot;Improved&quot; or &quot;Much Improved&quot; as Assessed by the Evaluating Investigator Using the Global Aesthetic Improvement Scale (GAIS)</title>
        <description>The Evaluating Investigator will assess the participant's temple area using the GAIS 5-point scale where: 2=much improved, 1=improved, 0=no change, -1=worse and -2=much worse. The percentage of participants who the Evaluating Investigator assesses as 2=much improved or 1=improved will be reported.</description>
        <time_frame>Month 3</time_frame>
        <population>Up to 189 subjects were planned; 1 subject was enrolled in the control_No Treatment arm. Terminated study; no treatment was administered and no analyses were conducted.</population>
        <group_list>
          <group group_id="O1">
            <title>VOLUMA® XC Treatment</title>
            <description>Participants will be treated with JUVÉDERM® VOLUMA® XC injectable gel in both temples (area above the eye). Participants are eligible for touch-up treatment 30 days later.</description>
          </group>
          <group group_id="O2">
            <title>Control_No Treatment</title>
            <description>No treatment is administered.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants &quot;Improved&quot; or &quot;Much Improved&quot; as Assessed by the Evaluating Investigator Using the Global Aesthetic Improvement Scale (GAIS)</title>
          <description>The Evaluating Investigator will assess the participant's temple area using the GAIS 5-point scale where: 2=much improved, 1=improved, 0=no change, -1=worse and -2=much worse. The percentage of participants who the Evaluating Investigator assesses as 2=much improved or 1=improved will be reported.</description>
          <population>Up to 189 subjects were planned; 1 subject was enrolled in the control_No Treatment arm. Terminated study; no treatment was administered and no analyses were conducted.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants &quot;Improved&quot; or &quot;Much Improved&quot; as Assessed by the Participant Using the GAIS</title>
        <description>The participant will assess their temple area using the GAIS 5-point scale where: 2=much improved, 1=improved, 0=no change, -1=worse and -2=much worse. The percentage of participants who assess themselves as 2=much improved or 1=improved will be reported.</description>
        <time_frame>Month 3</time_frame>
        <population>Up to 189 subjects were planned; 1 subject was enrolled in the control_No Treatment arm. Terminated study; no treatment was administered and no analyses were conducted.</population>
        <group_list>
          <group group_id="O1">
            <title>VOLUMA® XC Treatment</title>
            <description>Participants will be treated with JUVÉDERM® VOLUMA® XC injectable gel in both temples (area above the eye). Participants are eligible for touch-up treatment 30 days later.</description>
          </group>
          <group group_id="O2">
            <title>Control_No Treatment</title>
            <description>No treatment is administered.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants &quot;Improved&quot; or &quot;Much Improved&quot; as Assessed by the Participant Using the GAIS</title>
          <description>The participant will assess their temple area using the GAIS 5-point scale where: 2=much improved, 1=improved, 0=no change, -1=worse and -2=much worse. The percentage of participants who assess themselves as 2=much improved or 1=improved will be reported.</description>
          <population>Up to 189 subjects were planned; 1 subject was enrolled in the control_No Treatment arm. Terminated study; no treatment was administered and no analyses were conducted.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <desc>Up to 189 subjects were planned; 1 subject was enrolled in the control_No Treatment arm</desc>
      <group_list>
        <group group_id="E1">
          <title>VOLUMA® XC Treatment</title>
          <description>Participants will be treated with JUVÉDERM® VOLUMA® XC injectable gel in both temples (area above the eye). Participants are eligible for touch-up treatment 30 days later.</description>
        </group>
        <group group_id="E2">
          <title>Control_No Treatment</title>
          <description>No treatment is administered.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The TI is responsible for compliance with the protocol at the investigational site. A representative of Allergan will make frequent contact with the TI and his/her research staff and will conduct regular monitoring visits at the site to review subject and device accountability records for compliance with the protocol</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to low patient enrollment, the target number of participants needed to achieve target power and statistically reliable results was not met.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head</name_or_title>
      <organization>Allergan Sales LLC</organization>
      <phone>877-277-8566</phone>
      <email>IR-CTRegistration@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

